Steward Partners Investment Advisory’s 4D Molecular Therapeutics FDMT Stock Holding History

Steward Partners Investment Advisory’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.65K	Hold	500	–	–	﹤0.01%	3869
2026 Q1	$4.66K	Hold	500	–	–	﹤0.01%	3819
2025 Q4	$3.75K	Hold	500	–	–	﹤0.01%	3777
2025 Q3	$4.34K	Hold	500	–	–	﹤0.01%	3695
2025 Q2	$1.85K	Hold	500	–	–	﹤0.01%	3753
2025 Q1	$1.61K	Buy	+500	New	+$2.36K	﹤0.01%	3685

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Steward Partners Investment Advisory's FDMT Position: Q2 2026 in Review

Steward Partners Investment Advisory held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 500 shares worth $6.65K. The position accounts for ﹤0.01% of the portfolio, ranked #3869.

Steward Partners Investment Advisory first reported a position in FDMT in Q1 2025 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Steward Partners Investment Advisory held 500 shares of 4D Molecular Therapeutics worth $6.65K as of Q2 2026.
Steward Partners Investment Advisory left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3869 holding.
Steward Partners Investment Advisory first reported a position in 4D Molecular Therapeutics in Q1 2025 and has held it in 6 quarters since.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.